(Q38176154)

30 August 2017

title

Tailoring anti-TNF therapy in IBD: drug levels and disease activity (English)

1 reference

30 August 2017

0 references

0 references

1

Shomron Ben-Horin

1 reference

30 August 2017

Yehuda Chowers

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

7 January 2014

1 reference

Nature Reviews Gastroenterology & Hepatology

30 August 2017

published in

1 reference

30 August 2017

volume

11

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

243-255

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2013.253

30 August 2017

exact match

0 references

cites work

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Therapeutic drug monitoring of immunosuppressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Serum adalimumab concentration and clinical remission in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Review article: loss of response to anti-TNF treatments in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Taking immunogenicity assessment of therapeutic proteins to the next level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Optimizing anti-TNF treatments in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Predictors of early response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Practical application of anti-TNF therapy for luminal Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Therapeutic drug monitoring of biologics for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Assessing response and loss of response to biological therapies in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab prevents Crohn's disease recurrence after ileal resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab 10 mg/kg every 3 weeks for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Predicting response to Anti-TNF Agents for the treatment of crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Comparative effectiveness of infliximab and adalimumab for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.253

10.1038/NRGASTRO.2013.253

31 March 2020

Identifiers

DOI

1 reference

30 August 2017

1 reference